Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 3/20 | 0.49 |
| ▸ | GHSR | Q92847 | 6/20 | 0.46 |
| ▸ | MME | P08473 | 3/20 | 0.44 |
| ▸ | ECE1 | P42892 | 3/20 | 0.44 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL852503 | 0.83 | PIN1 (0.67) | PIN1MMEECE1NAALAD2CYP1A2 | |
| SCHEMBL19305346 | 0.77 | MMP9 (0.49) | MMETACR1 | |
| SCHEMBL28502441 | 0.77 | MMP9 (0.49) | MMETACR1 | |
| SCHEMBL13884234 | 0.77 | PIN1 (0.59) | PIN1MMEECE1CYP1A2AGTR2 | |
| SCHEMBL17007846 | 0.76 | GHSR (0.59) | GHSR | |
| SCHEMBL20397778 | 0.72 | PIN1 (0.54) | PIN1MMEECE1NAALAD2CYP1A2 | |
| SCHEMBL20397780 | 0.72 | PIN1 (0.54) | PIN1MMEECE1NAALAD2CYP1A2 | |
| SCHEMBL16758733 | 0.72 | FOLH1 (0.51) | MME | |
| SCHEMBL12899913 | 0.70 | ATM (0.49) | PIN1 | |
| SCHEMBL20204233 | 0.70 | PIN1 (0.57) | PIN1MMEECE1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278968-B2 | Imidazopyridine compounds | ASTELLAS PHARMA INC. (JP) | 2016-03-08 | — | — | US | disclosed |
| EP-2927231-A1 | IMIDAZOPYRIDINE COMPOUNDS | Astellas Pharma Inc. (JP) | 2015-10-07 | — | — | EP | disclosed |
| US-20150232464-A1 | IMIDAZOPYRIDINE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232464-A1 | IMIDAZOPYRIDINE COMPOUNDS | PRKG1, PDE3B, PDE3A | PIN1 1065/4885GHSR 1729/4885MME 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.